

AUDITED FINANCIAL RESULTS FOR THE QUARTER/ YEAR ENDED 31ST, MARCH, 2009

Rs. In Lacs

Sr. No.	Particulars	Quarter ended		Year ended	
		31.03.2009	31.03.2008	31.03.2009	31.03.2008
1	a) Net Sales / Income from operations	7198.06	8342.49	30185.85	31864.20
	b) Other operating income	161.87	16.96	331.71	34.38
	Total (1)	7359.93	8359.45	30517.56	31898.58
2	Expenditure				
	a) (Increase) / decrease in stock in trade	(135.90)	86.03	(1370.78)	(631.56)
	b) Consumption of raw materials	5024.06	5535.62	22298.56	22657.15
	c) Purchase of traded goods	--	--	--	--
	d) Employees cost	220.14	270.99	813.81	828.85
	e) Depreciation	247.71	236.04	1000.17	742.88
	f) Other expenditure	1321.21	1357.82	5175.88	5370.54
	Total (2)	6677.22	7486.50	27917.64	28967.86
3	Profit from operations before other income, interest and exceptional items (1-2)	682.71	872.95	2599.92	2930.72
4	Other income	0.45	0.45	1.80	1.80
5	Profit before interest and exceptional items (3+4)	683.16	873.40	2601.72	2932.52
6	Interest	399.18	366.79	1491.95	1295.85
7	Profit after interest but before exceptional items (5-6)	283.98	506.61	1109.77	1636.67
8	Exceptional items	--	--	--	--
9	Profit from ordinary activities before tax (7+8)	283.98	506.61	1109.77	1636.67
10	Tax Expenses	(291.93)	35.60	(159.65)	400.33
11	Net Profit from ordinary activities after tax (9-10)	575.91	471.01	1269.42	1236.34
12	Extraordinary Item (net of tax expense)	--	--	--	--
13	Net Profit for the period (11-12)	575.91	471.01	1269.42	1236.34
14	Paid-up equity share capital (Face value Rs.10/- Per Share)	1815.00	1338.00	1815.00	1338.00
15	Reserves excluding revaluation reserves	--	--	7939.30	4780.47
16	Earning per share (not annualised)				
	- Basic	3.71	3.67	8.18	10.26
	- Diluted	3.57	2.89	7.87	7.60
17	Public shareholding				
	- No of shares	8412047	6842047	8412047	6842047
	- % age	46.35	51.14	46.35	51.14
18	Promoters and promoter group shareholding				
	a) Pledged/encumbered				
	- Number of shares	400000	400000	400000	400000
	- %age of the total promoters' shareholding	4.11	6.12	4.11	6.12
	- % age of the total shareholding	2.20	2.99	2.20	2.99
	b) Non-encumbered				
	- Number of shares	9337953	6137953	9337953	6137953
	- %age of the total promoters' shareholding	95.89	93.88	95.89	93.88
	- % age of the total shareholding	51.45	45.87	51.45	45.87

Segment wise Revenue, Results and Capital Employed, under clause 41 of the Listing Agreement

(Rs. in Lacs)

Sr No	Particulars	Quarter ended		Accounting year ended	
		31.03.2009	31.03.2008	31.03.2009	31.03.2008
1	Segment Revenue (Net sales/income)				
	- Chemicals	4639.29	5750.72	21292.58	23304.46
	- Drugs	2521.29	2584.78	8791.08	8481.84
	- Unallocated	199.35	23.95	433.90	112.28
	Total	7359.93	8359.45	30517.56	31898.58
	Less : Inter segment revenue	--	--	--	--
	Net sales/income from operations	7359.93	8359.45	30517.56	31898.58
2	Segment Results				
	Profit/(loss) before tax and interest from each segment)				
	- Chemicals	326.75	712.08	1663.99	2398.95
	- Drugs	215.43	136.93	560.87	419.49
	Total	542.18	849.01	2224.86	2818.44
	Less :				
	Interest	399.18	366.79	1491.95	1295.85
	Other un-allocable expenditure net off un-allocable income	(140.98)	(24.39)	(376.86)	(114.08)
	Total Profit before tax & Extraordinary Items	283.98	506.61	1109.77	1636.67
3	Capital Employed				
	(Segment assets - Segment liabilities)				
	- Chemicals	6130.82	6041.41	6130.82	6041.41
	- Drugs	8159.92	7414.51	8159.92	7414.51
	- Unallocated including capital work in progress	21821.42	5388.72	21821.42	5388.72
	Total	36112.16	18844.64	36112.16	18844.64

Notes:

- During the quarter, the equity paid up capital has increased from Rs 1769.60 lacs to Rs 1815.00 lacs on the allotment of 4,54,000 equity shares on the conversion of warrants on 20.02.2009. Further, it has increased from Rs 1815.00 lacs to Rs 2121.67 lacs on the allotment of 30,66,664 equity shares on the conversion of debentures on 21.04.2009.
- The ongoing expansion cum backward and forward integration project with a CAPEX of Rs 256 crores is being implemented as per schedule and likely to be completed during the year 2009-10. The Company has incurred Rs 225 crores on the ongoing projects up to 31.05.2009.
- Status of Investor Complaints for the quarter ended 31.03.2009 is as under:

Complaints at the beginning of quarter	Complaints received during the quarter	Complaints Resolved	Complaints Pending
Nil	Nil	Nil	Nil

- Tax expense comprises current tax, fringe benefit tax and deferred tax.
- The figures of previous quarter/ year have been regrouped/ rearranged wherever necessary.
- The above results have been reviewed by the Audit & Risk Management Committee and taken on record by the Board of the Directors at their meeting held on 30th June, 2009.

By order of the Board

For IOL Chemicals and Pharmaceuticals Limited

Place: Ludhiana
Date: 30.06.2009

Sd/-
(Varinder Gupta)
Chairman and Managing Director